Page 11234..10..»

Archive for the ‘Stem Cell Negative’ Category

Stem Cell Banking Market 2020: Global Industry Overview By Size, Share, Trends, Growth Factors, Historical Analysis, Opportunities and Industry…

Sunday, December 29th, 2019

Zion Market Research analysts forecasts the latest report onGlobal Stem Cell Banking Market Is Expected to Reach Around USD 13.36 Billion By 2025, according to their latest report.

Read More...

Scientists hope MND cure is a step closer after stem cell breakthrough discovery – The National

Tuesday, December 24th, 2019

SCIENTISTS hope a cure for motor neurone disease (MND) is a step closer after a research breakthrough identified cells key to the degenerative condition. There is currently no known cure for MND, which causes signals from motor neurone nerve cells in the brain and spinal cord needed to control movement to gradually stop reaching the muscles. Notable people who have lived with MND include Scottish rugby star Doddie Weir and Stephen Hawking.

Read More...

CytoDyn Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative…

Monday, December 23rd, 2019

VANCOUVER, Washington, Dec.

Read More...

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID in Relapsed or Refractory Indolent Lymphoma – BioSpace

Monday, December 23rd, 2019

BEIJING, China and CAMBRIDGE, Mass., Dec.

Read More...

20 Things That Have Changed for the Better Since 2010 – 24/7 Wall St.

Monday, December 23rd, 2019

By Hristina ByrnesDecember 23, 2019 3:32 pm If you are someone who at least tries to stay informed about what is going on in the world, your faith in humanity may be long gone. Daily headlines are predominantly about negative subjects such as ugly politics, crime, and how we are killing the planet.

Read More...

A new role for a triple-negative breast cancer target – Penn: Office of University Communications

Sunday, December 22nd, 2019

Unlike almost every other organ, the mammary gland does not develop until after birth. And its unusually dynamic, shape-shifting during menstrual cycles, puberty, pregnancy, and lactation

Read More...

Why Proper Hydration Is Necessary for the Body to Function – Guardian Liberty Voice

Sunday, December 22nd, 2019

Some people believe that it is impossible to ionize water, others believe the product is too good to be true. It is important to note that the ionization of water can be tested using scientific measuring devices such as pH and ORP meters

Read More...

Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 – Science

Friday, December 13th, 2019

Interferon Insight Uncontrolled type I IFN activity has been linked to several human pathologies, but evidence implicating this cytokine response directly in disease has been limited. Here, Duncan et al.

Read More...

Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. – DocWire…

Friday, December 13th, 2019

This article was originally published here Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Res

Read More...

Stem Cell Therapy for Osteoarthritis Market Growth Scope Assessment 2019: Regeneus, Mesoblast, Asterias Biotherapeutics – Global Industry Analysis

Friday, December 13th, 2019

The Global Stem Cell Therapy for Osteoarthritis market report 2019-2026 provides basic and elementary information about the universal industry. The study report on the Stem Cell Therapy for Osteoarthritis market has been designed using a set of principal as well as subordinate methods which are accountable to offer accurate and meticulous information with respect to the Stem Cell Therapy for Osteoarthritis market dynamics, the recent industry landscape, and historical achievements.

Read More...

Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium – GlobeNewswire

Friday, December 13th, 2019

FLORHAM PARK, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief business officer of Cellectar, presented a poster at the AACR San Antonio Breast Cancer Symposium in San Antonio, TX. The poster, entitled: Preclinical evaluation of a novel phospholipid drug conjugate, CLR 2000045 with a combretastatin A-4 analogue for improved breast cancer therapy, featured data demonstrating potent in vivo activity in multiple animal models of breast cancer, including a model of triple negative breast cancer

Read More...

Interview with Gavin Jeffries from Fluicell: Cell Biology is at the Core of our Work – 3DPrint.com

Friday, December 13th, 2019

Getting to know cells well helps understand how organisms function. This is one of the aspects that drive scientists, researchers, and physicians to create bioprinting technology to generate living structures that can mimic the actual environment of human tissues

Read More...

Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug…

Wednesday, December 11th, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC patient preparation program were presented at the 61st Annual Meeting of the American Society of Hematology (ASH). These results, which were highlighted in an oral presentation at ASH by John Tisdale, M.D., Director, Molecular and Clinical Hematology Section, National Institutes of Health, showed the first-ever successful transplant of gene-modified cells in non-human primates using a targeted, single-agent antibody-drug conjugate (ADC), without the use of chemotherapy or radiation

Read More...

Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells – BioSpace

Wednesday, December 11th, 2019

The issuance of this patent highlights Lineages dominant position in the field of cell therapy, stated Brian M. Culley, CEO of Lineage. Our efforts to develop new treatments rely on well-characterized and NIH-approved human cell lines

Read More...

SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia – BioSpace

Wednesday, December 11th, 2019

Tbingen, Germany, 10 December 2019 -SYNIMMUNE GmbH, a biotechnology company focusing on the development of innovative and effective anti-tumor antibodies for orphan hematopoietic malignancies, announced today that interim results of its first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML) were presented at the 61stAmerican Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The data were presented in a poster titled Interim Results of a First in Human Study with the Fc-Optimized FLT3 Antibody FLYSYN for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Read More...

Why Sangamo Therapeutics Stock Sank Today – The Motley Fool

Wednesday, December 11th, 2019

What happened Shares of Sangamo Therapeutics (NASDAQ:SGMO) were sinking 11.7% lower as of 3:28 p.m. EST on Tuesday

Read More...

Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies | DNA RNA…

Wednesday, December 11th, 2019

DetailsCategory: DNA RNA and CellsPublished on Tuesday, 10 December 2019 10:40Hits: 255 - FasTCAR-19 (GC007F) shows a high response rate, with 34 of 35 evaluable r/r B-ALL patients achieving CR on Day 28, where 32 patients achieving MRD negative CR - Dual CAR-19-22 (GC022) shows sound safety profile and effectiveness, with 15/16 evaluable r/r B-ALL patients achieving MRD-CR on Day 28 - Dual CAR-BCMA-19 (GC012) demonstrates excellent tumor eliminating capabilities in preclinical study aligned with encouraging safety and efficacy data for r/r MM treatment SUZHOU, Chinaand SHANGHAI, China I December 9, 2019 I Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, held from December 7-10. Multiple pilot studies intend to evaluate the safety and efficacy of Gracell's first-in-class FasTCAR-19 (GC007F), Dual CAR-19-22 (GC012F) and Dual CAR-BCMA-19 (GC022F) cell therapy

Read More...

Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers – GlobeNewswire

Wednesday, December 11th, 2019

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome Data presented at 61st American Society of Hematology Annual Meeting form basis for advancement of AUTO1 into pivotal clinical trial in adult ALL Investor call to be held December 9 at 8:30 am ET / 1:30 pm GMT to review data LONDON, Dec. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL) announced today new data highlighting progress on its next-generation programmed T cell therapies to treat patients with acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The data were presented in oral presentations at the 61stAmerican Society of Hematology(ASH) Annual Meeting and Exposition inOrlando, FL

Read More...

Oral Azacitidine: First Maintenance Therapy for AML – Medscape

Wednesday, December 11th, 2019

ORLANDO, Florida For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival a new oral formulation of an old drug, azacitidine, known as CC-486 (Celgene). Dr Andrew Wei "Oral azacitidine represents a new therapeutic standard for patients with AML in remission," said lead author Andrew H.

Read More...

Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting – GlobeNewswire

Wednesday, December 11th, 2019

FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects Company Plans to Submit an IND Application for FT819 during 1H20 SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc

Read More...

Page 11234..10..»


2020 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick